Statement from AMCP CEO Susan A. Cantrell on President Trump’s New Tariffs

Topic(s):

Legislation & Regulation

Alexandria, Va., February 3, 2025 – The Academy of Managed Care Pharmacy (AMCP) issued the following statement from AMCP CEO Susan A. Cantrell, MHL, RPh, CAE, regarding President Trump’s new and proposed tariffs on U.S. imports from Canada, Mexico, and China:

“Although President Trump’s new and proposed tariffs aim to level the playing field between American industries and our foreign competitors, we are concerned about the unintended, adverse consequences they may have on the cost of medicines in the U.S.

Tariffs on China and other key countries in the global pharmaceutical supply chain could lead to increased costs for medicines, ultimately burdening U.S. patients and the health care system. Many critical medications and raw materials are sourced internationally, and imposing tariffs risks driving up prices, creating supply disruptions, and impeding patient access to essential treatments.

With that in mind, we respectfully urge caution when instituting tariffs that may negatively impact prescription drug costs and potentially contribute to drug shortages. We ask the administration to consider exemptions for pharmaceutical products or deliberate implementation timelines in order to maintain efficient and affordable delivery to patients. That way, those patients who need these prescriptions the most are protected.”

About AMCP
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, biopharmaceutical professionals, and other stakeholders leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models. Visit www.amcp.org.

Related

CMS Letter
Letters, Statements & Analysis

AMCP Letter on the Medicare and Medicaid Programs for Contract Year 2026

AMCP shared comments with Centers for Medicare & Medicaid Services (CMS) on the proposed 2026 Policy and Technical Changes to the Medicare Advantage (MA) Program. We applaud CMS’ efforts to address obesity and emphasized the importance of managing costs. AMCP urged CMS to issue guidance on managing drugs in this class to effectively treat obesity as a chronic disease. On the Medicare Transaction Facilitator, we advised CMS to avoid adding unnecessary costs and administrative burdens. We support CMS’ focus on increasing access to generics, biosimilars, and other affordable medications. Lastly, we provided insights on proposed changes to Star Ratings, ensuring member perspectives are represented.
Legislation & Regulation
White House
Letters, Statements & Analysis

AMCP Policy Brief - Initial Trump Administration Health Care Executive Orders

On Jan. 20, 2025, newly inaugurated President Trump signed dozens of Executive Orders concerning a number of G.O.P. policy priorities, including but not limited to: immigration and border security, trade and economic policy, the federal workforce, energy and environmental policy, law and order, and social policies. While health care was not a primary focus of these executive actions, President Trump did withdraw the United States from the World Health Organization and revoked several Biden-era actions related to health policy. Executive Orders are directives from the president that manage operations of the federal government, have the effect of law, may be promulgated by government agencies, and may be overturned by judicial review if they lack support by existing law or the Constitution.
Legislation & Regulation

Upcoming Events

Visit the AMCP Calendar

AMCP offers a wide variety of educational opportunities, from events and webinars to online training.

Annual Conference:

Learn More
AMCP 2025 Logo No Date


March 31—April 3 • • • Houston, Texas